Biosimilars: Forging a New Path to Accessibility Amid the Reshaping of the Global Biologics Industry
Chime Vision | Inaugural Issue
Editorial Note
As the global biopharmaceutical industry evolves at an unprecedented pace, technological breakthroughs, shifting industry dynamics, and changing market demands are increasingly intertwined—driving a new cycle of transformation. Chime Vision is a thought leadership series launched by Chime Biologics. From the perspective of an industry practitioner, we aim to share our observations and reflections on industry development, technological trends, and global markets. Through rational analysis and open dialogue, we hope to engage with our clients, partners, and the broader community in documenting the trajectory of the biopharmaceutical industry in this era.
Over the past one to two decades, rapid advances in the scientific understanding of drug mechanisms and in antibody engineering have fueled a surge in biologics pipelines. This expanding wave of innovative originator biologics will, in turn, provide a continuous foundation for the future growth of the biosimilars market.
Against this backdrop, emerging economies that performed strongly in the previous wave of globalization—particularly China, with its vast industrial scale—have actively positioned themselves in the next phase of high-end manufacturing transformation. Almost without exception, biologics manufacturing has become a strategic focal point.
Looking back, Chime Biologics was fortunate to seize the historic opportunity presented by the first wave of biosimilar development in emerging markets more than a decade ago. By committing early and deeply, we also benefited from China’s rapid, across-the-board industrial advancement—including in the pharmaceutical sector. Along this journey, we have witnessed, participated in, and contributed to the evolution of biosimilars in China—from initial establishment, through challenges, to today’s active participation in global competition.
Looking ahead, we believe the global biosimilars market is entering a new chapter.
On the supply side, the rapid expansion of manufacturing capacity, together with the growth of upstream bioprocessing industries, is fundamentally reshaping the global division of labor in biologics supply chains—transforming cost structures and improving affordability.
On the demand side, pricing pressures in developed markets, aging populations in emerging economies, and increasing purchasing power driven by economic growth are all contributing to rising demand. Even in more mature economies with slower growth, the continued decline in biosimilar prices will expand access to treatment for broader patient populations.
Together, these forces will continue to expand the global biosimilars market—until, for certain products, biosimilars may evolve into widely accessible global public goods, delivering tangible benefits to patients worldwide.
As we step into this new phase, the previous cycle of industry adjustment is drawing to a close, while a new wave of global biologics supply chain restructuring is accelerating.
Aligned with this momentum, Chime Biologics is embarking on large-scale capacity expansion and accelerating its global footprint. We are committed to contributing to the broader adoption of biosimilars worldwide and to becoming a leading representative of China-based biologics manufacturers expanding globally.
At this pivotal moment—where profound shifts in the global biologics manufacturing landscape intersect with Chime Biologics’ rapid growth in global operations and capacity—we are both confident and deeply aware of our responsibilities.
It is for this reason that we have launched Chime Vision.
Through this platform, we aim to share:
- Insights drawn from our development journey
- Progress achieved through ongoing practice
- Perspectives on future industry trends
with our clients, employees, partners, peers, and the broader communities across industry, finance, science, academia, and media.
May the stories we build together be captured in words that inspire progress—serving as a vivid reflection of the global biopharmaceutical industry in this defining era.
About Chime Biologics
Chime Biologics is a leading global CDMO, focused on ensuring our customers' success in delivering innovative biologics as well as biosimilars to patients across the world. Chime Biologics can support customers end to end, from pre-clinical support and cell line development through to clinical and commercial manufacturing of drug substance and drug product. Employing our state-of-the-art capabilities in our Europe Innovation Hub (Basel, CH), China Innovation Hub (Shanghai, CN), Development & Manufacturing Campus (Wuhan, CN) and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the biologics industry. With over 600 skilled employees, we share a common goal to make cutting-edge biologics affordable and accessible to patients worldwide, fulfilling our commitment to improving human health globally.
